SCHEMBL1050348

SCHEMBL1050348

N#Cc1cc(-c2cn(S(=O)(=O)c3ccccc3)c3ncccc23)cc(NCc2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 4/20 0.60
CTSL P07711 1/20 0.43
HTR6 P50406 4/20 0.42
CDK2 P24941 4/20 0.42
DAPK3 O43293 2/20 0.42
ROCK2 O75116 2/20 0.42
PRKD3 O94806 2/20 0.42
PAK4 O96013 2/20 0.42
PIM1 P11309 2/20 0.42
PRKACA P17612 2/20 0.42
FLT3 P36888 2/20 0.42
CSNK1A1 P48729 2/20 0.42
CLK2 P49760 2/20 0.42
GSK3B P49841 2/20 0.42
CDK7 P50613 2/20 0.42
CDK9 P50750 2/20 0.42
PRKX P51817 2/20 0.42
JAK3 P52333 2/20 0.42
CAMK2D Q13557 2/20 0.42
DYRK1A Q13627 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15190122 0.87 CDC7 (0.57) CDC7CTSLHTR6CDK2DAPK3
SCHEMBL1050301 0.87 CDK2 (0.57) CDC7HTR6CDK2DAPK3ROCK2
SCHEMBL1046359 0.83 DAPK3 (0.50) CDC7HTR6CDK2DAPK3ROCK2
SCHEMBL1045563 0.82 CDC7 (0.59) CDC7HTR6CDK2GSK3BCDK1
SCHEMBL1050793 0.80 CDC7 (0.61) CDC7HTR6CDK2DAPK3ROCK2
SCHEMBL1050791 0.80 CDC7 (0.61) CDC7HTR6CDK2DAPK3ROCK2
SCHEMBL1585614 0.80 HTR6 (0.48) CTSLHTR6CDK2CCNE1CCNC
SCHEMBL15705225 0.79 L3MBTL1 (0.45) CDC7HTR6DRD2HTR7L3MBTL1
SCHEMBL1050710 0.79 HTR6 (0.43) CDC7HTR6CDK2CDK1CCNE1
SCHEMBL1045577 0.75 CDC7 (1.00) CDC7CDK2DAPK3ROCK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885CTSL 3285/4885HTR6 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.